CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE
✉ Email this page to a colleague
All Clinical Trials for methylphenidate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000268 ↗ | Cocaine Abuse and Attention Deficit Disorder - 3 | Completed | New York State Psychiatric Institute | N/A | 1995-05-01 | The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder |
| NCT00000268 ↗ | Cocaine Abuse and Attention Deficit Disorder - 3 | Completed | National Institute on Drug Abuse (NIDA) | N/A | 1995-05-01 | The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder |
| NCT00003266 ↗ | Methylphenidate in Treating Patients With Melanoma | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-06-01 | RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks. |
| NCT00003266 ↗ | Methylphenidate in Treating Patients With Melanoma | Completed | Eastern Cooperative Oncology Group | Phase 3 | 1999-06-01 | RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks. |
| NCT00012584 ↗ | Treatment of Youth With ADHD and Anxiety | Completed | National Institute of Mental Health (NIMH) | N/A | 2000-11-01 | The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate. |
| NCT00015054 ↗ | Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 | Completed | Cincinnati MDRU | Phase 2 | 1998-09-01 | The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for methylphenidate
Condition Name
Clinical Trial Locations for methylphenidate
Trials by Country
Clinical Trial Progress for methylphenidate
Clinical Trial Phase
Clinical Trial Sponsors for methylphenidate
Sponsor Name
